Celgene to Pay $280 Million to Settle Fraud Suit Over Cancer Drugs

The lawsuit accused the pharmaceutical company of marketing Thalomid and Revlimid for unapproved use on a broader range of cancers.
By KATIE THOMAS from NYT Health http://ift.tt/2uvw3P1
via IFTTT
Drugs (Pharmaceuticals), Suits and Litigation (Civil), Cancer
Source The New York Times
Làm đẹp Blog 247